The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4

Biochemical and Biophysical Research Communications

Volumn 367, Issue 1, 2008, Pages 41-46

  Juncadella, Ignacio J ^a   Garg, Renu ^b   Bates, Tonya C ^a   Olivera, Elias R ^a   Anguita, Juan ^a,b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

gp120 CD4 interaction; HIV; Salp15

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; SALIVA PROTEIN; SALP15 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IXODES SCAPULARIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HELA CELLS; HIV; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; SALIVARY PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; IXODES SCAPULARIS;

EID: 38049037423     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.12.104     Document Type: Article

References (29)

1. Doms R.W. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Top HIV Med. 12 (2004) 100-103
2. Vermeire K., and Schols D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin. Investig. Drugs 14 (2005) 1199-1212
3. Moore J.P., Sattentau Q.J., Klasse P.J., and Burkly L.C. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol. 66 (1992) 4784-4793
4. Ryu S.E., Kwong P.D., Truneh A., Porter T.G., Arthos J., Rosenberg M., Dai X.P., Xuong N.H., Axel R., Sweet R.W., et al. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348 (1990) 419-426
5. Wilkinson R.A., Piscitelli C., Teintze M., Cavacini L.A., Posner M.R., and Lawrence C.M. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J. Virol. 79 (2005) 13060-13069
6. Wu H., Myszka D.G., Tendian S.W., Brouillette C.G., Sweet R.W., Chaiken I.M., and Hendrickson W.A. Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proc Natl Acad Sci USA 93 (1996) 15030-15035
7. Briant L., Signoret N., Gaubin M., Robert-Hebmann V., Zhang X., Murali R., Greene M.I., Piatier-Tonneau D., and Devaux C. Transduction of activation signal that follows HIV-1 binding to CD4 and CD4 dimerization involves the immunoglobulin CDR3-like region in domain 1 of CD4. J. Biol. Chem. 272 (1997) 19441-19450
8. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
9. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
10. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
11. Gallo S.A., Finnegan C.M., Viard M., Raviv Y., Dimitrov A., Rawat S.S., Puri A., Durell S., and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614 (2003) 36-50
12. Arthos J., Deen K.C., Chaikin M.A., Fornwald J.A., Sathe G., Sattentau Q.J., Clapham P.R., Weiss R.A., McDougal J.S., Pietropaolo C., et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57 (1989) 469-481
13. Clayton L.K., Hussey R.E., Steinbrich R., Ramachandran H., Husain Y., and Reinherz E.L. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. Nature 335 (1988) 363-366
14. Sutor G.C., Dreikhausen U., Vahning U., Jurkiewicz E., Hunsmann G., Lundin K., and Schedel I. Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV. J. Immunol. 149 (1992) 1452-1461
15. Santoro F., Vassena L., and Lusso P. Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol. 27 (2004) 17-29
16. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., and Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug. Discov. 3 (2004) 215-225
17. + T cell activation. Immunity 16 (2002) 849-859
18. Garg R., Juncadella I.J., Ramamoorthi N., Ashish, Ananthanarayanan S.K., Thomas V., Rincon M., Krueger J.K., Fikrig E., Yengo C.M., and Anguita J. Cutting edge: CD4 is the receptor for the tick saliva immunosuppressor, Salp15. J. Immunol. 177 (2006) 6579-6583
19. Dowd C.S., Leavitt S., Babcock G., Godillot A.P., Van Ryk D., Canziani G.A., Sodroski J., Freire E., and Chaiken I.M. Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry 41 (2002) 7038-7046
20. Vita C., Drakopoulou E., Vizzavona J., Rochette S., Martin L., Menez A., Roumestand C., Yang Y.S., Ylisastigui L., Benjouad A., and Gluckman J.C. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 96 (1999) 13091-13096
21. Ciminale V., Felber B.K., Campbell M., and Pavlakis G.N. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res. Hum. Retroviruses 6 (1990) 1281-1287
22. Chesebro B., and Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62 (1988) 3779-3788
23. Deng H.K., Unutmaz D., KewalRamani V.N., and Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388 (1997) 296-300
24. Jeeninga R.E., Hoogenkamp M., Armand-Ugon M., de Baar M., Verhoef K., and Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J. Virol. 74 (2000) 3740-3751
25. Klaver B., and Berkhout B. Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus. J. Virol. 68 (1994) 3830-3840
26. Juncadella I.J., Garg R., Ananthnarayanan S.K., Yengo C.M., and Anguita J. T-cell signaling pathways inhibited by the tick saliva immunosuppressor, Salp15. FEMS Immunol. Med. Microbiol. 49 (2007) 433-438
27. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
28. Moebius U., Clayton L.K., Abraham S., Harrison S.C., and Reinherz E.L. The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J. Exp. Med. 176 (1992) 507-517
29. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., de Souza M.S., Birx D.L., McCutchan F.E., and Polonis V.R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79 (2005) 6089-6101